Similar articles

• [Therapy of arterial occlusive disease].

  Bollinger A. Bollinger A. Verh Dtsch Ges Inn Med. 1990;96:702-6. Verh Dtsch Ges Inn Med. 1990. PMID: 2092509 Review. German. No abstract available.
• [The role of prostacycline, thromboxane A2 and prostaglandins in platelet aggregation (author's transl)].

  Herman AG. Herman AG. Rev Med Brux. 1981 Mar;2(3):251-7. Rev Med Brux. 1981. PMID: 7015444 French. No abstract available.
• Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.

  Shaw LA, Batey AJ, Coker SJ. Shaw LA, et al. Br J Pharmacol. 1997 Jul;121(5):875-82. doi: 10.1038/sj.bjp.0701208. Br J Pharmacol. 1997. PMID: 9222543 Free PMC article.
• The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists.

  Radomski M. Radomski M. Acta Physiol Pol. 1985 May-Jun;36(3):153-64. Acta Physiol Pol. 1985. PMID: 3915630 Review.
• Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.

  Humphrey PP, Hallet P, Hornby EJ, Wallis CJ, Collington EW, Lumley P. Humphrey PP, et al. Circulation. 1990 Jan;81(1 Suppl):I42-52; discussion I59-60. Circulation. 1990. PMID: 2136817